Applied BioMath, an industry leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), announced its participation at the mRNA-Based Therapeutics Summit, occurring July 26-28, 2023 in Boston, MA.
Diana Marcantonio, PhD, Director of Biology at Applied BioMath will present, "Applications of a Quantitative Systems Pharmacology (QSP) Model of Lipid Nanoparticle (LNP) mRNA delivery for the Treatment of Crigler-Najjar Syndrome Type 1" on Friday, July 28th at 2:30 p.m. in the afternoon session of the Translation track. In this presentation, Dr. Marcantonio will discuss how the "LNP-encapsulated mRNA targeting an intracellular protein in vivo" model in Applied BioMath Assess™ was used to explore key design features for an LNP-delivered mRNA gene therapy, and how a similar QSP model was developed and calibrated to data from a Gunn rat animal model and used for preclinical-to-clinical translation and first-in-human dose projections.
Applied BioMath Assess™ is a point-and-click, MID3 software to assess efficacy, safety, and therapeutic index for early-stage biotherapeutics.
"In this presentation, we hope to demonstrate how modeling and simulation approaches can be applied throughout the R&D pipeline," said John Burke, Ph.D., Co-founder, President and CEO of Applied BioMath. "From using Applied BioMath Assess™ in early discovery to establish feasibility and dose projections to capturing all of the biological and pharmacological knowledge in a QSP model to support translation from preclinical to clinical studies and first-in-human studies."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!